© 1998 by Oxford University Press
Should Selection of Adjuvant Chemotherapy for Patients With Breast Cancer Be Based on erbB-2 Status?
Gary M. Clark
| You have reached the most complete version of this article accessible without further authentication.
More complete versions are available. Link to article |
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limbergen, P. Berteloot, F. Amant, I. Vergote, and M. R. Christiaens Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer Ann. Onc., November 1, 2005; 16(11): 1755 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Dressler, D. A. Berry, G. Broadwater, D. Cowan, K. Cox, S. Griffin, A. Miller, J. Tse, D. Novotny, D. L. Persons, et al. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients J. Clin. Oncol., July 1, 2005; 23(19): 4287 - 4297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kauraniemi, T. Kuukasjarvi, G. Sauter, and A. Kallioniemi Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer Am. J. Pathol., November 1, 2003; 163(5): 1979 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Lodge, J J Anderson, W J Gullick, B Haugk, R C F Leonard, and B Angus Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 J. Clin. Pathol., April 1, 2003; 56(4): 300 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Zujewski "Build Quality in"--HER2 Testing in the Real World J Natl Cancer Inst, June 5, 2002; 94(11): 788 - 789. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kauraniemi, M. Barlund, O. Monni, and A. Kallioniemi New Amplified and Highly Expressed Genes Discovered in the ERBB2 Amplicon in Breast Cancer by cDNA Microarrays Cancer Res., November 1, 2001; 61(22): 8235 - 8240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Thor Are Patterns of HER-2/neu Amplification and Expression Among Primary Tumors and Regional Metastases Indicative of Those in Distant Metastases and Predictive of Herceptin Response? J Natl Cancer Inst, August 1, 2001; 93(15): 1120 - 1121. [Full Text] [PDF]
|
|
|
|
|
|
S. Paik, J. Bryant, E. Tan-Chiu, G. Yothers, C. Park, D. L. Wickerham, and N. Wolmark HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst, December 20, 2000; 92(24): 1991 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Linderholm, K. Grankvist, N. Wilking, M. Johansson, B. Tavelin, and R. Henriksson Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment J. Clin. Oncol., April 7, 2000; 18(7): 1423 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. H. Jarvinen, M. Tanner, V. Rantanen, M. Barlund, A. Borg, S. Grenman, and J. Isola Amplification and Deletion of Topoisomerase II{alpha} Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer Am. J. Pathol., March 1, 2000; 156(3): 839 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Isola, L. Chu, S. DeVries, K. Matsumura, K. Chew, B. M. Ljung, and F. M. Waldman Genetic Alterations in ERBB2-amplified Breast Carcinomas Clin. Cancer Res., December 1, 1999; 5(12): 4140 - 4145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bieche, P. Onody, I. Laurendeau, M. Olivi, D. Vidaud, R. Lidereau, and M. Vidaud Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications Clin. Chem., August 1, 1999; 45(8): 1148 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System J. Clin. Oncol., July 1, 1999; 17(7): 1983 - 1983. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||